SRNE, US83587F2020

Sorrento appeal is dismissed: what it means for Sorrento Therapeutics stock

Published on 10/14/2026 at 00:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The docket lists a September 29, 2026 voluntary dismissal in Texas. For Sorrento Therapeutics stock this means a November 6, 2026 reporting date.

Appeal and liquidation timeline

A voluntary appeal dismissal was entered on September 29, 2026.
A Texas bankruptcy decision carried the reference 2026 WL 1791033 on June 21, 2026.
Sorrento Therapeutics is scheduled to report on November 6, 2026.

SRNE, US83587F2020, Illustration mit AI erstellt.

Sorrento appeal is dismissed: what it means for Sorrento Therapeutics stock is a question of legal finality rather than operating momentum. A voluntary dismissal filed September 28, 2026, and entered September 29, 2026, closed an individual bankruptcy appeal involving Sorrento, according to Law360.

What the dismissal means for liquidation

The case sits within Sorrento's Chapter 11 liquidation history. A September 2026 appeal notice followed an earlier Texas bankruptcy decision that limited challenges to the confirmed plan and assigned claims to a liquidation trust, according to Jones Day.

For investors tracking the security, the legal timeline is more concrete than the company's historical drug pipeline. Sorrento filed for Chapter 11 protection on February 13, 2023, while its liquidating plan was confirmed on December 13, 2023, according to Jones Day.

Three dates define the case

On June 21, 2026, the bankruptcy court issued the decision identified as 2026 WL 1791033, according to Jones Day. On September 18, 2026, a clerk's notice recorded an appeal filing in the Texas Southern District, according to Law360. The September 28 filing and September 29 entry of the voluntary dismissal form the latest dated step in the sequence.

Reporting date sets the next marker

Sorrento Therapeutics is scheduled to release its next earnings report on November 6, 2026, according to Investing.com. The same page identifies SRNE, the OTC Markets listing and the ISIN US83587F2020, while the company profile describes Sorrento as a biotechnology business.

Liquidation remains the key company fact

The company entered Chapter 11 protection in 2023, and the confirmed plan governs the legal context surrounding the September 2026 appeal activity. Sorrento's corporate website identifies the issuer as Sorrento Therapeutics, Inc., while structured company data classify it in Healthcare and Biotechnology.

Market context: Latest market reports.